VENTURA COUNTY HEALTH CARE PLAN

# Preferred Specialty Management (PSM) Policy for Hepatitis C Virus (HCV) Direct-Acting Antivirals (DAAs)

Effective Date: 7/24/18
Date Developed: 6/22/18 by Catherine Sanders, MD
Last Approval Date: 7/24/18, 1/22/19

**(Archived 1/22/19)**

## PREFERRED SPECIALTY MANAGEMENT (PSM) POLICY FOR HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS (DAAs)

**DRUGS AFFECTED:**

- Daklinza™ (daclatasvir tablets – Bristol Meyers Squibb)
- Epclusa® (velpatasvir/sofosbuvir – Gilead)
- Harvoni® (ledipasvir/sofosbuvir tablets – Gilead)
- Mavyret (glecaprevir/pibrentasvir-AbbVie)
- Olysio® (simeprevir tablets – Janssen)
- Sovaldi® (sofosbuvir tablets – Gilead)
- Technivie ™ (co-formulated ombitasvir, paritaprevir, and ritonavir tablets – AbbVie)
- Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets, co-packaged – AbbVie)
- Viekira XR™ (dasabuvir/ombitasvir/paritaprevir/ritonavir extended-release tablets – AbbVie)
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir tablets-Gilead)
- Zepatier™ (grazoprevir/elbasvir tablets – Merck)

## Initial criteria required:

1. The patient is ≥ 18 years of age, or for Harvoni or Sovaldi + Ribavirin, patient is ≥ 12 years of age or weighting ≥ 35 kg, AND
2. The medication is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or a liver transplant physician; AND
3. The patient meets ONE of the following conditions (A, B or C)
   A. The patient has been documented as having a hepatic fibrosis score correlating with **Metavir Stage F2** or higher as assessed by an invasive (liver biopsy) OR non-invasive method (e.g. aspartate aminotransferase-to-platelet ratio index [APRI] score, fibrosis-4 index [FIB-4], FibroScan, FibroTest/FibroSURE); OR
   B. The patient has severe extrahepatic manifestations placing them at high risk for severe complications of their HCV (patient must meet criteria i or ii)
      i. Type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations (e.g. vasculitis); OR
      ii. Proteinuria, nephrotic syndrome, or membranoproliferative glomerular nephritis; OR
   C. The patient meets BOTH of the following conditions (i and ii)
      i. The patient is at high-risk of transmitting HCV (patient must meet ONE of the following criteria a or b):
         a. The patient is on long-term (≥ 3 months) hemodialysis; OR
         b. The patient is a healthcare worker whose daily activities put them in contact with blood and/or needles; AND

ii. The patient has been counseled on ways to decrease transmission of HCV and minimize the risk of reinfection with HCV

## Preferred Products:

**Genotype 1:** Epclusa, Harvoni, Mavyret, Viekira pak (with or without ribavirin), Viekira XR (with or without ribavirin), and Vosevi. *Patients with genotype 1 requesting Daklinza, Olysio, Sovaldi or Zepatier will be directed to a preferred product.*

**Genotype 2:** Epclusa, Mavyret, and Vosevi.

**Genotype 3:** Epclusa, Mavyret and Vosevi. *Patients with genotype 3 requesting Daklinza and/or Sovaldi will be directed to a preferred product*

**Genotype 4:** Epclusa, Harvoni, Mavyret, Technivie, and Vosevi. *Patients with genotype 4 requesting Zepatier will be directed to a preferred product.*

**Genotype 5 or 6:** Epclusa, Harvoni, Mavyret, and Vosevi.

## Secondary criteria required:

Please see the individual PRIOR AUTHORIZATION DRUG GUIDELINES for the drug requested if it meets initial criteria.

VENTURA COUNTY
HEALTH CARE PLAN

**Revision History:**
Date Created: 6/22/18 by C. Sanders, MD
Date Reviewed/No Updates: 7/24/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 7/24/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

| Revision Date | Content Revised (Yes/No) | Contributors | Review/Revision Notes |
|---|---|---|---|
| 7/24/18 | No | Catherine Sanders, MD | Effective Date |
| 1/22/19 | No | Catherine Sanders, MD; Robert Sterling, MD | Archived – check ESI |